Salvadó, Gemma http://orcid.org/0000-0002-5210-9230
Horie, Kanta http://orcid.org/0000-0001-7736-2614
Barthélemy, Nicolas R. http://orcid.org/0000-0003-4937-2860
Vogel, Jacob W. http://orcid.org/0000-0001-6394-9940
Pichet Binette, Alexa http://orcid.org/0000-0001-5218-3337
Chen, Charles D. http://orcid.org/0000-0001-6698-1268
Aschenbrenner, Andrew J.
Gordon, Brian A. http://orcid.org/0000-0003-2109-2955
Benzinger, Tammie L. S. http://orcid.org/0000-0002-8114-0552
Holtzman, David M.
Morris, John C.
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Janelidze, Shorena http://orcid.org/0000-0003-2869-8378
Ossenkoppele, Rik
Schindler, Suzanne E.
Bateman, Randall J. http://orcid.org/0000-0002-7729-1702
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Article History
Received: 3 May 2023
Accepted: 20 February 2024
First Online: 21 March 2024
Competing interests
: O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. J.W.V. is supported by the SciLifeLab & Wallenberg Data-Driven Life Science Program (grant: KAW 2020.0239). K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received salary from Eisai. Washington University, R.J.B. and D.M.H. have equity ownership interest in C2N Diagnostics. R.J.B. and D.M.H. receive income from C2N Diagnostics for serving on the scientific advisory board. K.H., N.R.B. and R.J.B. may receive income based on technology (methods to detect MTBR tau isoforms and use thereof) licensed by Washington University to C2N Diagnostics. D.M.H. may receive income based on technology (antibodies to mid-domain of tau) licensed by Washington University to C2N Diagnostics. R.J.B. has received honoraria as a speaker, consultant or advisory board member from Amgen and Roche. D.M.H. is on the scientific advisory board of Genentech, Denali and Cajal Neurosciences and consults for Alector and Asteroid. N.R.B. is a co-inventor on the following US patent applications: ‘Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer’s disease and other tauopathies’ (PCT/US2020/046224); ‘CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies’ (PCT/US2022/022906); and ‘Methods of diagnosing and treating based on site-specific tau phosphorylation’ (PCT/US2019/030725). N.R.B. may receive royalty income based on technology licensed by Washington University to C2N Diagnostics. The remaining authors declare no competing interests.